8-K: STAAR Surgical Confirms Alcon Merger After Go-Shop Expiration

STAAR Surgical Company announced the expiration of its go-shop period without receiving any competing acquisition proposals, validating its merger agreement with Alcon Inc.

Summary

• The go-shop period, pursuant to the amended merger agreement with Alcon Inc., expired at 11:59 p.m. Eastern Time on December 6, 2025.
• No competing acquisition proposals were received during the go-shop period.
• STAAR, with the assistance of its financial advisor, Citi, actively solicited acquisition proposals from 21 third parties, including financial sponsors and potential strategic acquirers.
• Only two of the 21 parties signed non-disclosure agreements (NDAs) and engaged in discussions with STAAR management.
• Parties previously identified as A, B, and C did not sign non-disclosure agreements to receive information regarding STAAR.
• The outcome of the go-shop process discredits allegations from Broadwood Partners, L.P. regarding ignored inbound interest and unrealistic assumptions about potential bidders.
• The STAAR Board believes the go-shop results confirm that its initial sale process and decision to merge with Alcon produced the best buyer for the company.

Sentiment

Score: 7

Explanation: The expiration of the go-shop period without competing offers provides certainty regarding the previously announced merger with Alcon, validating the Board's strategic decision. While no higher bids emerged, the confirmation of the transaction path is a positive for stakeholders by reducing uncertainty.

Positives

• The expiration of the go-shop period without competing offers provides certainty regarding the previously announced merger with Alcon Inc.
• The results validate the STAAR Board's initial strategic decision and sale process, confirming Alcon as the optimal buyer.
• The outcome discredits allegations from a significant shareholder, Broadwood Partners, regarding the Board's handling of potential acquisition interest.

Negatives

• No higher bids emerged during the go-shop period, indicating that the Alcon offer is likely the best available valuation for the company at this time.
• Only a small fraction (2 out of 21) of the solicited parties showed sufficient interest to sign non-disclosure agreements and engage in detailed discussions.

Risks

• The occurrence of any event, change, or circumstances that could lead to the termination of the Alcon merger agreement or cause the transaction to be delayed or fail.
• Failure to obtain approval of the proposed transaction from STAAR's stockholders.
• Failure to obtain certain required regulatory approvals or to satisfy any other closing conditions for the completion of the proposed transaction within expected timeframes or at all.
• Disruption of management's attention from ongoing business operations due to the proposed transaction.
• The effect of the announcement of the proposed transaction on the ability to retain and hire key personnel and maintain relationships with customers, suppliers, and other business partners, or on operating results and business generally.
• Inability to meet expectations regarding the timing and completion of the transaction.
• The outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction.
• The possibility that STAAR's stock price may decline significantly if the proposed transaction is not consummated.

Future Outlook

The company anticipates proceeding with the previously announced merger with Alcon Inc., subject to stockholder approval, regulatory approvals, and satisfaction of other closing conditions. The go-shop process confirmed the Alcon offer as the best available, solidifying the path forward for the transaction.

Management Comments

• "The STAAR Board conducted a thoughtful sale process before the transaction was announced that was based on its extensive M&A experience, careful consideration of potential alternatives and its informed view of the ophthalmic space."
• "The results of this go-shop confirm that the process that the Board pursued before approving the merger agreement – and its knowledge of STAAR’s business, risks and opportunities – produced the best buyer for STAAR."
• "Now is the Right Time to Sell the Business and Alcon is the Right Buyer."

Industry Context

STAAR Surgical is a global leader in phakic intraocular lenses (IOLs) with its EVO ICL product line. The confirmed merger with Alcon, a major player in the broader eye care industry, represents a significant consolidation. This move is likely driven by a desire to leverage Alcon's extensive distribution network and R&D capabilities, potentially enhancing the reach and development of STAAR's specialized IOL technology. The absence of competing bids during the go-shop period suggests that, within the current ophthalmic market, the Alcon offer was perceived as a fair valuation, or that other potential strategic or financial buyers did not see sufficient incremental value to make a superior offer.

Stakeholder Impact

• Shareholders: Will vote on the proposed merger and will receive consideration if the merger completes. There is a risk of stock price decline if the merger is not consummated.
• Employees: Potential risks related to disruption of management's attention, and the ability to retain and hire key personnel due to the proposed transaction.
• Customers and Suppliers: Potential risks related to maintaining relationships due to the proposed transaction.

Next Steps

• Stockholders are urged to read all relevant documents filed or to be filed with the SEC, including the Proxy Statement, and to make a voting decision on the proposed transaction.
• Obtain required regulatory approvals for the merger.
• Satisfy any other closing conditions to the completion of the proposed transaction.

Key Dates

Recommendation

The expiration of the go-shop period without any superior offers solidifies the path towards the merger with Alcon. For existing shareholders, holding shares until the transaction closes is advisable to realize the merger consideration. New investors should consider the limited upside to the merger price versus the potential downside if the merger unexpectedly fails, making a 'hold' a prudent stance for those already invested or considering short-term arbitrage.

Keywords

STAAR Surgical, Alcon, Merger, Acquisition, Go-Shop, Ophthalmic, ICL, Phakic IOL, Vision Correction, Medical Devices